Lyell Immunopharma, Inc.
General ticker "LYEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $299.0M (TTM average)
Lyell Immunopharma, Inc. follows the US Stock Market performance with the rate: 46.6%.
Estimated limits based on current volatility of 4.5%: low 15.93$, high 17.42$
Factors to consider:
- Total employees count: 300 (+33.9%) as of 2024
- Top business risk factors: Insufficient funding, Labor/talent shortage/retention, Market volatility, Product commercialization failure, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.77$, 46.57$]
- 2026-12-31 to 2027-12-31 estimated range: [8.22$, 26.61$]
Short-term LYEL quotes
Long-term LYEL plot with estimates
Financial data
| YTD | 2025-12-31 |
|---|---|
| Operating Revenue | $0.04MM |
| Operating Expenses | $203.81MM |
| Operating Income | $-203.77MM |
| Non-Operating Income | $-70.67MM |
| R&D Expense | $158.68MM |
| Income(Loss) | $-274.45MM |
| Profit(Loss)* | $-274.45MM |
| Stockholders Equity | $248.20MM |
| Assets | $340.05MM |
| Operating Cash Flow | $-150.02MM |
| Capital expenditure | $0.78MM |
| Investing Cash Flow | $54.10MM |
| Financing Cash Flow | $50.41MM |
| Earnings Per Share** | $-16.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.